BOSTON SCIENTIFIC CORP

Boston Scientific’s May 2026 moves: a $2 billion share‑repurchase boost EPS slightly, while a $1.5 billion stake in MiRus aims to capture growth in the high‑margin TAVR market.

Boston Scientific’s latest clinical data on FARAPULSE, WATCHMAN, and EMBLEM shows higher success and lower risk, boosting reimbursement prospects and market share in cardiac devices.

Boston Scientific’s Q1 earnings cut outlook amid rising R&D spend and regulatory pressures, yet shows growth in AI‑driven tech and global expansion opportunities.

Boston Scientific Q1 earnings beat forecasts, but 2026 guidance was cut—driven by reimbursement pressures and competition. Stock gains amid S&P rally highlight the firm’s steady demand in electrophysiology and cardiovascular devices, yet investors s…

Boston Scientific’s stock slipped modestly amid S&P 500 volatility, reflecting market‑wide pressure rather than company news—an insight for investors monitoring sector trends.

Boston Scientific faces a dual‑front battle: a securities‑fraud lawsuit threatens shares while a $5.4 B merger with Penumbra could boost revenue and margins by up to 9 %. Learn how analysts are recalibrating price targets and why investors should wa…

Boston Scientific Corp. balances litigation risk, investor confidence, and regulatory compliance, with steady stock performance and major institutional buys underscoring its robust medical‑device fundamentals.

Boston Scientific Corp. shows steady growth and strong innovation in minimally invasive cardiology and electrophysiology, positioning it for continued upward market performance.

Boston Scientific expands its Farapulse CE‑marking to treat persistent atrial fibrillation, boosting clinical value and revenue potential in Europe while navigating reimbursement and operational challenges.

Boston Scientific’s Q1 2026 results, TD Cowen strategy talks and ownership shifts signal new growth, AI‑driven device innovation, ESG focus, and supply‑chain resilience ahead of the stock’s next move.